advertising
-
1
Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11: 415, 1998.
-
2
Howland RH: Understanding the placebo effect: part 1. Placebo use in clinical trials. J Psychosoc Nurs Ment Health Serv 46: 17, 2008.
-
3
Price DD, Finniss DG, Benedetti F: A comprehensive review of the placebo effect: recent advances and current thought. Ann Rev Psychol 59: 565, 2008.
-
4
Gupta AK, Ryder JE, Bluhm R, et al: Onychomycosis: quality of studies. J Cutan Med Surg 7: 312, 2003.
-
5
Baran R, Tosti A, Hartmane I, et al: An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 23: 773, 2009.
-
6
Drake LA, Shear NH, Arlette JP, et al: Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 37: 740, 1997.
-
7
Elewski BE, Scher RK, Aly R, et al: Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis 59: 217, 1997.
-
8
Elewski BE, El Charif M, Cooper KD, et al: Reactivity to trichophytin antigen in patients with onychomycosis: effect of terbinafine. J Am Acad Dermatol 46: 371, 2002.
-
9
Elewski BE, Ghannoum MA, Mayser P, et al: Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venereol 27: 287, 2013.
-
10
Elewski B, Pollak R, Ashton S, et al: A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 166: 389, 2012.
-
11
Elewski BE, Rich P, Pollak R, et al: Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 68: 600, 2013.
-
12
Goodfield MJ, Andrew L, Evans EG: Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 304: 1151, 1992.
-
13
Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 43: S70, 2000.
-
14
Gupta A, Leonardi C, Stoltz R, et al: A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 19: 437, 2005.
-
15
Jones HE, Zaias N: Double-blind, randomized comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol 35: 589, 1996.
-
16
Ling MR, Swinyer LJ, Jarratt MT, et al: Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38: S95, 1998.
-
17
Odom R, Daniel CR, Aly R: A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 35: 110, 1996.
-
18
Scher RK, Breneman D, Rich P, et al: Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38: S77, 1998.
-
19
Svejgaard EL, Brandrup F, Kragballe K, et al: Oral terbinafine in toenail dermatophytosis: a double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol 77: 66, 1997.
-
20
Syed TA, Qureshi ZA, Ali SM, et al: Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop Med Int Health 4: 284, 1999.
-
21
Watson A, Marley J, Ellis D, et al: Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 33: 775, 1995.
-
22
Gupta AK, Maddin S, Arlette J, et al: Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatol Treat 11: 33, 2000.
-
23
Miller FG, Kaptchuk TJ: The power of context: reconceptualizing the placebo effect. J R Soc Med 101: 222, 2008.
-
24
Hu SW: Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 146: 1132, 2010.
-
25
Bell-Syer SEM, Khan SM, Torgerson DJ: Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst Rev 10: CD003584, 2012.
-
26
Crawford F, Harris R, Williams HC: Are placebo-controlled trials of creams for athlete's foot still justified? Br J Dermatol 159: 773, 2008.
-
27
Daniel CR III: The diagnosis of nail fungus infection revisited. Arch Dermatol 136: 1162, 2000.
Placebo Cure Rates in the Treatment of Onychomycosis
Mediprobe Research Inc, London, ON, Canada.
Search for other papers by Aditya K. Gupta in
Current site
Google Scholar
PubMed
Search for other papers by Maryse Paquet in
Current site
Google Scholar
PubMed
Placebo cure rates vary among randomized clinical trials for onychomycosis, but the factors influencing these cure rates have not been systematically investigated. The PubMed database and reference sections of relevant publications were searched for randomized controlled trials of dermatophyte toenail onychomycosis that included a placebo control and that assessed cure rates. From 21 studies, the pooled mean ± SD placebo cure rates regarding mycological, clinical, and complete cure were 8.7% ± 3.7%, 3.4% ± 2.2%, and 1.2% ± 1.4%, respectively. There was no statistically significant difference between oral and topical treatments. None of the cure rates significantly correlated with any of the participant or study design characteristics analyzed. Placebo cure rates in randomized controlled trials of toenail onychomycosis are relatively low and are independent of the study characteristics.
advertising
